Omalizumab: The Monoclonal Antibody for Asthma and Allergies
What is Omalizumab?
Omalizumab is a monoclonal antibody used to treat severe asthma and chronic urticaria (hives). It works by blocking the action of IgE antibodies, which play a key role in the allergic response.
How Omalizumab Works
Omalizumab binds to IgE antibodies, preventing them from attaching to mast cells and releasing histamine. This reduces the inflammatory response associated with asthma and allergic reactions.
When to Use Omalizumab
● Severe Asthma: Omalizumab is used for severe allergic asthma in patients who do not respond to standard asthma medications.
● Chronic Urticaria: It is also used for chronic hives (urticaria) in patients who do not respond to antihistamines.
Dosage
● Adult Dose for Asthma: Starting dose of 150 mg subcutaneously every 2-4 weeks, depending on the patient’s weight and baseline IgE levels. For individuals weighing > 90 kg the dose is 300 mg every 4 weeks.
● Pediatric Dose: For children aged 6-11 years, the dose is based on weight and IgE levels, typically administered every 2-4 weeks.
20-40 kg: 75 mg every 4 weeks,
40-90 kg: 150 mg every 4 weeks,
90-150 kg : 300 mg every 4 weeks
Side Effects
● Common Effects: Injection site reactions, headache, and fatigue.
● Serious Adverse Effects: Anaphylaxis, severe allergic reactions, and increased risk of infections.
Common brands: Emzumab, Bolstran